Endometrial carcinoma: past, present, and future

[1] Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer. 2018; 103: 356–387.

[2] Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang Y, et al. Type i and II endometrial cancers: have they different risk factors? Journal of Clinical Oncology. 2013; 31: 2607–2618.

[3] Prat J, Gallardo A, Cuatrecasas M, Catasús L. Endometrial carcinoma: pathology and genetics. Pathology. 2007; 39: 72–87.

[4] Matoda M, Omatsu K, Yamamoto A, Nomura H, Tanigawa T, Kawamata Y, et al. Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer. European Journal of Gynaecological Oncology. 2014; 35: 224–229.

[5] Perrone AM, Marcoberardino BB Di, Rossi MM, et al. Laparoscopic versus laparotomic approach to endometrial cancer. European Journal of Gynaecological Oncology. 2012; 33: 376–381.

[6] Ditto A, Casarin J, Pinelli C, Perrone AM, Scollo P, Martinelli F, et al. Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: a multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group. European Journal of Cancer. 2020; 140: 1–10.

[7] Schuurman TN, Stiekema A, Schagen van Leeuwen JH, Verheijen RHM. Systematic lymphadenectomy in patients with clinical stage II endometrial carcinoma: a case report and review of the literature. European Journal of Gynaecological Oncology. 2012; 33: 530–533.

[8] Pendlebury A, Radeva M, Rose PG. Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy. Journal of Surgical Oncology. 2021; 123: 1292–1298.

[9] Bogani G, Papadia A, Buda A, Casarin J, Di Donato V, Gasparri ML, et al. Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multiinstitutional study. Gynecologic Oncology. 2021; 161: 122–129.

[10] Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radio-therapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. The Lancet. 2000; 355: 1404–1411.

[11] Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[12] Espinosa I, De Leo A, D’Angelo E, Rosa-Rosa JM, Corominas M, Gonzalez A, et al. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Human Pathology. 2018; 72: 100–106.

[13] Dondi G, Coluccelli S, De Leo A, Ferrari S, Gruppioni E, Bovicelli A, et al. An analysis of clinical, surgical, pathological and molecular characteristics of endometrial cancer according to mismatch repair status. A multidisciplinary approach. International Journal of Molecular Sciences. 2020; 21: 1–17.

[14] IARC Publications Website. Female Genital Tumours. 2020. Available at: https://publications.iarc.fr/Book-And-Report-Ser ies/Who-Classification-Of-Tumours/Female-Genital-Tumours-2020 (Accessed: 24 June 2021).

[15] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecologic Cancer. 2021; 31: 12–39.

[16] De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, et al. What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics. 2021; 11: 697.

[17] Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. British Journal of Cancer. 2018; 119: 1067–1074.

[18] Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Annals of Oncology. 2018; 29: 1180–1188.

[19] De Leo A, de Biase D, Lenzi J, Barbero G, Turchetti D, Grillini M, et al. Arid1a and ctnnb1/β-catenin molecular status affects the clinicopathologic features and prognosis of endometrial carcinoma: Implications for an improved surrogate molecular classification. Cancers. 2021; 13: 1–22.